Patents Assigned to HTD Bio Corp.
  • Detection of desmoglein-2 in cancers of epithelial origin
    Patent number: 12669505
    Abstract: The disclosure provides methods of diagnosing, prognosing and stratifying cancers in a patient, comprising detecting elevated expression of desmoglein-2 (DSG-2) in a sample of the cancer and referencing that level to historic data to determine treatment regimen, stage, and prognosis of a patient.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: June 30, 2026
    Assignees: HTD Bio Corp., University of Washington
    Inventors: Darrick Carter, Jiho Kim, Andre Lieber